Precision BioSciences to Attend Healthcare Conference

Gene editing company will participate in the 25th Annual Needham Virtual Healthcare Conference.

Apr. 8, 2026 at 5:45pm

Got story updates? Submit your updates here. ›

A vibrant, neon-outlined DNA double helix structure glowing against a dark background, symbolizing the innovative gene editing technology developed by Precision BioSciences.Precision BioSciences showcases its gene editing expertise at a premier healthcare investment conference.Durham Today

Precision BioSciences, Inc., a clinical-stage gene editing company based in Durham, North Carolina, has announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference. The company utilizes its proprietary ARCUS platform to develop innovative gene therapies.

Why it matters

Precision BioSciences' participation in this high-profile healthcare investment conference signals the company's continued progress in advancing its gene editing technologies and therapies. As a clinical-stage company, its presence at this event provides an opportunity to showcase its pipeline and engage with potential investors and partners.

The details

Precision BioSciences, a Nasdaq-listed company, will present and host one-on-one meetings with investors during the 25th Annual Needham Virtual Healthcare Conference. The conference is a premier event for the healthcare and life sciences industry, attracting leading companies, investors, and industry experts.

  • The 25th Annual Needham Virtual Healthcare Conference will take place on April 8, 2026.

The players

Precision BioSciences, Inc.

A clinical-stage gene editing company that utilizes its proprietary ARCUS platform to develop innovative gene therapies.

Got photos? Submit your photos here. ›

The takeaway

Precision BioSciences' participation in the prestigious Needham Healthcare Conference underscores the company's progress in advancing its gene editing technologies and therapies, and provides an opportunity to engage with potential investors and partners as it continues to drive innovation in the field of gene editing.